Davide Matino at BIC 2025: Phase 3 Data on Fitelparvovec for Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
”Updated Ph3 data on gene therapy for haemophilia A with giroctocogene fitelparvovec (AAV6, 3e13 vg/kg in 74 participants), presented by Davide Matino at BIC meeting 2025:
~35% of participants maintained near-normal to normal FVIII activity (40–150%) at 2 years post-infusion
Durability data is impressive: sustained efficacy approaches three years of follow-up, demonstrating the transformative potential of this AAV6 approach
- Slow decline pattern:
– Year 1 mean: 51.7%
– Year 2 mean: 51.9% (stabilization)
– Year 3 mean: 40.7% (median: 38.0%)
Note: Only 8 participants had 3-year follow-up
- Sustained FVIII levels >5% in >80% of participants at 15 and at 24 months
- 98.3% reduction in treated bleeding episodes (4.08 → 0.07 ABR post-infusion)
- Transient FVIII activity >150% in nearly 50%, managed with low-dose prophylactic DOAC in 30%
- One participant developed a thrombotic event (history of thrombosis and risk factors)
- 2 participants resumed FVIII prophylaxis
Generally well-tolerated safety profile with manageable ALT elevations (ALT ↑ in 61%)
High rate of infusion-related reactions (75%), but no discontinuation of study drug administration
One case of new cancer at 35 months (oral SCC, not related to study drug); in total 2 malignancies reported
One case of FVIII inhibitor development (more to follow tomorrow!)
Despite these results, Pfizer has discontinued this program and terminated their collaboration with Sangamo Therapeutics in December 2024”
More from BIC 2025 featured in Hemostasis Today.
-
Jun 23, 2026, 18:27Advancing Gene Therapy Research for Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jun 23, 2026, 18:17What Every ITP Patient Wants to Know – ITP Support Association
-
Jun 23, 2026, 18:13Ahsan Fareed: Exploring Heart Failure Readmissions in Iron Deficiency Anemia
-
Jun 23, 2026, 18:09Swarnava Roy: Key Findings on Stress Erythropoiesis and Mitochondrial Retention in RBCs
-
Jun 23, 2026, 17:40Hossam El Benawi: How do We Predict Recurrence Post LVT Resoultion?
-
Jun 23, 2026, 17:39Nicolas Gendron: Do We Really Need All These Hemostasis Tests in Patients on DOACs?
-
Jun 23, 2026, 17:33Maité Mulkers: Time is Brain, and One Reason is That a Thrombus Develops Over Time
-
Jun 23, 2026, 17:32Dhargam Aljebouri: Honoured to Be Part of the Young Professionals Breakfast at ISBT 2026
-
Jun 23, 2026, 17:27Dianne E. van der Wal: Phenotype and Activation of the Endothelium in ET at ISTH 2026